33 We surpassed our vision of supporting global innovator partners in bringing 25 new medicines to market by 2025, crossing this milestone two years ahead of schedule. We are the only CRDMO among the listed Indian peers that can conduct development activities in close proximity to our customers, and transfer technology for manufacturing back to India. We have strategic presence in the innovation hubs with our locations in Greater Boston Facility and the Manchester Facility. It facilitates access to the latest research trends, talented global workforce, and potential collaboration within innovation hubs, while our facilities in India offer our customers cost-competitive advantage for conducting drug discovery research activities at scale, development and large-scale commercial production of products. We are able to co create value with our customers with our ability to support them from discovery to commercialisation as well as absorb technology quickly from the customers operations or their existing CDMO Our co-located technical competencies spans biology, chemistry and DMPK services within our Hyderabad facility where our scientific services are conducted by a single CRO for time and cost efficiencies, enables an “integrated drug discovery” process for our customers. We have biology capabilities both in the Hyderabad facility and the Greater Bostonfacility, which enables us to engage an increasing share of customers to co- locate their discovery activities with us. Through our Greater Boston Facility, we have developed and transferred Customer Centricity over seven biology assays that have enabled us to onboard seven drug discovery customers for conducting larger discovery programs in India for FY 24. We are also one of the few CROs to have a dedicated R&D facility for one of our customers. By having a dedicated R&D facility demonstrates our ability to serve our customers with a comprehensive set of capabilities and long- term commitment by the customer. In 2023, one of our customers chose us through the request-for-proposal process to establish a specialized integrated drug discovery R&D centre within our premises to address the needs of this specific customer. This facility is staffed with a dedicated team of 83 professionals. Information protection We support innovation for our customers and therefore i nformation confidentiality is our highest priority. This is one of the pillars to sustainably co-create value. Our approach has served us well all these years and has earned us the trust of our customers. There is strong leadership commitment to IP protection that percolates through every level in the organisation. And most importantly, we have built a robust customer data protection regime on seven core pillars: 1. Need to know data access 2. Fully paperless/ electronic data in R&D and manufacturing 3. QA-controlled document issuance 4. Information/ cybersecurity controls on servers, email, & mobile devices 5. HR policies and processes to prevent data loss 6. Physical security 7. Restrictive external interface Our CDMO portfolio constituted 49 “late phase” molecules. 34 of which underwent process development in our R&D facilities before entering Phase III clinical trials, and the remaining 15 were transferred to our manufacturing facilities from another facility. We also have a portfolio of over 100 products in various stages of development across pre-clinical, Phase I and Phase II clinical trial stages.
RkJQdWJsaXNoZXIy MTIwMDc4NQ==